Introduction, Anatomical Regions

4 · Body Part

• 1Subcutaneous Tissue

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 1Daratumumab and Hyaluronidase-fihj

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• 1Subcutaneous Tissue

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 2Talquetamab Antineoplastic

7 · Qualifier

• 9New Technology Group 9

4 · Body Part

• 1Subcutaneous Tissue

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 4Teclistamab Antineoplastic

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• 1Subcutaneous Tissue

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 4Elamipretide

7 · Qualifier

• CNew Technology Group 12

4 · Body Part

• 1Subcutaneous Tissue

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 6Dasiglucagon

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 1Subcutaneous Tissue

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• FOther New Technology Therapeutic Substance

7 · Qualifier

• 5New Technology Group 5

4 · Body Part

• 1Subcutaneous Tissue

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• GREGN-COV2 Monoclonal Antibody
• HOther New Technology Monoclonal Antibody
• KLeronlimab Monoclonal Antibody

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• 1Subcutaneous Tissue

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• LElranatamab Antineoplastic

7 · Qualifier

• 9New Technology Group 9

4 · Body Part

• 1Subcutaneous Tissue

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• SCOVID-19 Vaccine Dose 1

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• 1Subcutaneous Tissue

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• SEpcoritamab Monoclonal Antibody

7 · Qualifier

• 9New Technology Group 9

4 · Body Part

• 1Subcutaneous Tissue

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• TCOVID-19 Vaccine Dose 2

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• 1Subcutaneous Tissue

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• TRozanolixizumab-noli Monoclonal Antibody

7 · Qualifier

• BNew Technology Group 11

4 · Body Part

• 1Subcutaneous Tissue

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• UCOVID-19 Vaccine

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• 1Subcutaneous Tissue

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• VCOVID-19 Vaccine Dose 3

7 · Qualifier

• 7New Technology Group 7

4 · Body Part

• 1Subcutaneous Tissue

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• WCaplacizumab

7 · Qualifier

• 5New Technology Group 5

4 · Body Part

• 1Subcutaneous Tissue

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• WCOVID-19 Vaccine Booster

7 · Qualifier

• 7New Technology Group 7

4 · Body Part

• 2Muscle

5 · Approach

• 0Open

6 · Device / Substance / Technology

• DEngineered Allogeneic Thymus Tissue

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• 2Muscle

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• SCOVID-19 Vaccine Dose 1
• TCOVID-19 Vaccine Dose 2
• UCOVID-19 Vaccine

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• 2Muscle

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• VCOVID-19 Vaccine Dose 3
• WCOVID-19 Vaccine Booster
• YOther New Technology Monoclonal Antibody

7 · Qualifier

• 7New Technology Group 7

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 0Spesolimab Monoclonal Antibody

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 0Alpha1-proteinase Inhibitor
• 1Anitocabtagene Autoleucel Immunotherapy

7 · Qualifier

• BNew Technology Group 11

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 3Bentracimab, Ticagrelor Reversal Agent
• 4Cefepime-taniborbactam Anti-infective

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 5Narsoplimab Monoclonal Antibody

7 · Qualifier

• 7New Technology Group 7

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 5Mosunetuzumab Antineoplastic

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 5Ceftobiprole Medocaril Anti-infective

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 6Afamitresgene Autoleucel Immunotherapy

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 6Landiolol Antiarrhythmic

7 · Qualifier

• CNew Technology Group 12

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 7Coagulation Factor Xa, Inactivated

7 · Qualifier

• 2New Technology Group 2

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 7Tabelecleucel Immunotherapy

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 7Zimislecel Allogeneic Stem Cell-Derived Islet Cell Therapy

7 · Qualifier

• CNew Technology Group 12

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 8Treosulfan

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 8Obecabtagene Autoleucel

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 9Ceftolozane/Tazobactam Anti-infective

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 9Inebilizumab-cdon

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 9Odronextamab Antineoplastic

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• ACiltacabtagene Autoleucel

7 · Qualifier

• 7New Technology Group 7

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• BCytarabine and Daunorubicin Liposome Antineoplastic

7 · Qualifier

• 3New Technology Group 3

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• BOrca-T Allogeneic T-cell Immunotherapy

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• CEngineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous

7 · Qualifier

• 7New Technology Group 7

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• CZanidatamab Antineoplastic
• DDonislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• ERemdesivir Anti-infective

7 · Qualifier

• 5New Technology Group 5

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• FOther New Technology Therapeutic Substance

7 · Qualifier

• 3New Technology Group 3

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• FOther New Technology Therapeutic Substance

7 · Qualifier

• 5New Technology Group 5

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• FNon-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• FValoctocogene Roxaparvovec-rvox

7 · Qualifier

• BNew Technology Group 11

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• GSarilumab

7 · Qualifier

• 5New Technology Group 5

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• GREGN-COV2 Monoclonal Antibody

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• GEngineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic

7 · Qualifier

• 7New Technology Group 7

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• HTocilizumab

7 · Qualifier

• 5New Technology Group 5

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• HOther New Technology Monoclonal Antibody

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• HAxicabtagene Ciloleucel Immunotherapy
• JTisagenlecleucel Immunotherapy
• KIdecabtagene Vicleucel Immunotherapy

7 · Qualifier

• 7New Technology Group 7

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• KSulbactam-Durlobactam

7 · Qualifier

• 9New Technology Group 9

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• LCD24Fc Immunomodulator

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• LLifileucel Immunotherapy
• MBrexucabtagene Autoleucel Immunotherapy

7 · Qualifier

• 7New Technology Group 7

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• MEmapalumab-lzsg Anti-IFNy Monoclonal Antibody

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• NLisocabtagene Maraleucel Immunotherapy

7 · Qualifier

• 7New Technology Group 7

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• NTarlatamab-dlle Antineoplastic

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• PGlofitamab Antineoplastic

7 · Qualifier

• 9New Technology Group 9

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• PAztreonam-avibactam Anti-infective

7 · Qualifier

• BNew Technology Group 11

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• QTagraxofusp-erzs Antineoplastic

7 · Qualifier

• 5New Technology Group 5

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• QPosoleucel

7 · Qualifier

• 9New Technology Group 9

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• QIloprost

7 · Qualifier

• BNew Technology Group 11

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• RRezafungin

7 · Qualifier

• 9New Technology Group 9

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• RLetetresgene Autoleucel

7 · Qualifier

• BNew Technology Group 11

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• SIobenguane I-131 Antineoplastic
• WCaplacizumab

7 · Qualifier

• 5New Technology Group 5

4 · Body Part

• 3Peripheral Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• WFosfomycin Anti-infective

7 · Qualifier

• BNew Technology Group 11

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 0Spesolimab Monoclonal Antibody

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 0Alpha1-proteinase Inhibitor
• 1Anitocabtagene Autoleucel Immunotherapy

7 · Qualifier

• BNew Technology Group 11

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 3Bentracimab, Ticagrelor Reversal Agent
• 4Cefepime-taniborbactam Anti-infective

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 5Narsoplimab Monoclonal Antibody

7 · Qualifier

• 7New Technology Group 7

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 5Mosunetuzumab Antineoplastic

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 5Ceftobiprole Medocaril Anti-infective

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 6Afamitresgene Autoleucel Immunotherapy

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 6Landiolol Antiarrhythmic

7 · Qualifier

• CNew Technology Group 12

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 7Coagulation Factor Xa, Inactivated

7 · Qualifier

• 2New Technology Group 2

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 7Tabelecleucel Immunotherapy
• 8Treosulfan

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 8Obecabtagene Autoleucel

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 9Ceftolozane/Tazobactam Anti-infective

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 9Inebilizumab-cdon

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 9Odronextamab Antineoplastic

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• ACiltacabtagene Autoleucel

7 · Qualifier

• 7New Technology Group 7

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• BCytarabine and Daunorubicin Liposome Antineoplastic

7 · Qualifier

• 3New Technology Group 3

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• BOrca-T Allogeneic T-cell Immunotherapy

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• CEngineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous

7 · Qualifier

• 7New Technology Group 7

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• CZanidatamab Antineoplastic

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• ERemdesivir Anti-infective

7 · Qualifier

• 5New Technology Group 5

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• FOther New Technology Therapeutic Substance

7 · Qualifier

• 3New Technology Group 3

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• FOther New Technology Therapeutic Substance

7 · Qualifier

• 5New Technology Group 5

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• FNon-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• FValoctocogene Roxaparvovec-rvox

7 · Qualifier

• BNew Technology Group 11

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• GSarilumab

7 · Qualifier

• 5New Technology Group 5

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• GREGN-COV2 Monoclonal Antibody

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• GEngineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic

7 · Qualifier

• 7New Technology Group 7

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• HTocilizumab

7 · Qualifier

• 5New Technology Group 5

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• HOther New Technology Monoclonal Antibody

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• HAxicabtagene Ciloleucel Immunotherapy
• JTisagenlecleucel Immunotherapy
• KIdecabtagene Vicleucel Immunotherapy

7 · Qualifier

• 7New Technology Group 7

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• KSulbactam-Durlobactam

7 · Qualifier

• 9New Technology Group 9

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• LCD24Fc Immunomodulator

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• LLifileucel Immunotherapy
• MBrexucabtagene Autoleucel Immunotherapy

7 · Qualifier

• 7New Technology Group 7

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• MEmapalumab-lzsg Anti-IFNy Monoclonal Antibody

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• NLisocabtagene Maraleucel Immunotherapy

7 · Qualifier

• 7New Technology Group 7

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• NTarlatamab-dlle Antineoplastic

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• PGlofitamab Antineoplastic

7 · Qualifier

• 9New Technology Group 9

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• PAztreonam-avibactam Anti-infective

7 · Qualifier

• BNew Technology Group 11

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• QTagraxofusp-erzs Antineoplastic

7 · Qualifier

• 5New Technology Group 5

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• QPosoleucel

7 · Qualifier

• 9New Technology Group 9

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• QIloprost

7 · Qualifier

• BNew Technology Group 11

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• RRezafungin

7 · Qualifier

• 9New Technology Group 9

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• RLetetresgene Autoleucel

7 · Qualifier

• BNew Technology Group 11

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• SIobenguane I-131 Antineoplastic
• WCaplacizumab

7 · Qualifier

• 5New Technology Group 5

4 · Body Part

• 4Central Vein

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• WFosfomycin Anti-infective

7 · Qualifier

• BNew Technology Group 11

4 · Body Part

• 5Peripheral Artery

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 4Stem Cells, Somatic

7 · Qualifier

• BNew Technology Group 11

4 · Body Part

• 5Peripheral Artery

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• TMelphalan Hydrochloride Antineoplastic

7 · Qualifier

• 9New Technology Group 9

4 · Body Part

• 6Cerebral Ventricle

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 2CPI-601 Enzyme Replacement Therapy

7 · Qualifier

• BNew Technology Group 11

4 · Body Part

• DMouth and Pharynx

5 · Approach

• XExternal

6 · Device / Substance / Technology

• 3Maribavir Anti-infective

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• DMouth and Pharynx

5 · Approach

• XExternal

6 · Device / Substance / Technology

• 8Uridine Triacetate

7 · Qualifier

• 2New Technology Group 2

4 · Body Part

• DMouth and Pharynx

5 · Approach

• XExternal

6 · Device / Substance / Technology

• FOther New Technology Therapeutic Substance

7 · Qualifier

• 5New Technology Group 5

4 · Body Part

• DMouth and Pharynx

5 · Approach

• XExternal

6 · Device / Substance / Technology

• JQuizartinib Antineoplastic

7 · Qualifier

• 9New Technology Group 9

4 · Body Part

• DMouth and Pharynx

5 · Approach

• XExternal

6 · Device / Substance / Technology

• KSabizabulin

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• DMouth and Pharynx

5 · Approach

• XExternal

6 · Device / Substance / Technology

• MBaricitinib

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• DMouth and Pharynx

5 · Approach

• XExternal

6 · Device / Substance / Technology

• NSER-109

7 · Qualifier

• 9New Technology Group 9

4 · Body Part

• DMouth and Pharynx

5 · Approach

• XExternal

6 · Device / Substance / Technology

• VXanomeline and Trospium Chloride

7 · Qualifier

• BNew Technology Group 11

4 · Body Part

• EEar(s)

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 3Lunsotogene Parvec-cwha via Intracochlear Infusion

7 · Qualifier

• BNew Technology Group 11

4 · Body Part

• GUpper GI

5 · Approach

• 7Via Natural or Artificial Opening

6 · Device / Substance / Technology

• 3Maribavir Anti-infective
• KSabizabulin

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• GUpper GI

5 · Approach

• 7Via Natural or Artificial Opening

6 · Device / Substance / Technology

• MBaricitinib

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• GUpper GI

5 · Approach

• 8Via Natural or Artificial Opening Endoscopic

6 · Device / Substance / Technology

• 8Mineral-based Topical Hemostatic Agent

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• HLower GI

5 · Approach

• 7Via Natural or Artificial Opening

6 · Device / Substance / Technology

• 3Maribavir Anti-infective
• KSabizabulin

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• HLower GI

5 · Approach

• 7Via Natural or Artificial Opening

6 · Device / Substance / Technology

• MBaricitinib

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• HLower GI

5 · Approach

• 7Via Natural or Artificial Opening

6 · Device / Substance / Technology

• XBroad Consortium Microbiota-based Live Biotherapeutic Suspension

7 · Qualifier

• 8New Technology Group 8

4 · Body Part

• HLower GI

5 · Approach

• 8Via Natural or Artificial Opening Endoscopic

6 · Device / Substance / Technology

• 8Mineral-based Topical Hemostatic Agent

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• JCoronary Artery, One Artery
• KCoronary Artery, Two Arteries
• LCoronary Artery, Three Arteries
• MCoronary Artery, Four or More Arteries

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• HPaclitaxel-Coated Balloon Technology, One Balloon
• JPaclitaxel-Coated Balloon Technology, Two Balloons
• KPaclitaxel-Coated Balloon Technology, Three Balloons
• LPaclitaxel-Coated Balloon Technology, Four or More Balloons

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• QCranial Cavity and Brain

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 1Eladocagene exuparvovec

7 · Qualifier

• 6New Technology Group 6

4 · Body Part

• QCranial Cavity and Brain

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• 5Ifezuntirgene Inilparvovec

7 · Qualifier

• CNew Technology Group 12

4 · Body Part

• UJoints

5 · Approach

• 0Open

6 · Device / Substance / Technology

• CRecombinant Human Bone Morphogenetic Protein-2 with Collagen Scaffold

7 · Qualifier

• CNew Technology Group 12

4 · Body Part

• UJoints

5 · Approach

• 0Open

6 · Device / Substance / Technology

• GVancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System

7 · Qualifier

• ANew Technology Group 10

4 · Body Part

• UJoints

5 · Approach

• 0Open
• 3Percutaneous
• 4Percutaneous Endoscopic

6 · Device / Substance / Technology

• XPeptide Enhanced Bone Void Filler

7 · Qualifier

• BNew Technology Group 11

4 · Body Part

• VBones

5 · Approach

• 0Open

6 · Device / Substance / Technology

• BVancomycin-eluting Bone Void Filler

7 · Qualifier

• CNew Technology Group 12

4 · Body Part

• VBones

5 · Approach

• 0Open

6 · Device / Substance / Technology

• PGentamicin-eluting Bone Void Filler

7 · Qualifier

• 7New Technology Group 7

4 · Body Part

• VBones

5 · Approach

• 3Percutaneous

6 · Device / Substance / Technology

• WAGN1 Bone Void Filler

7 · Qualifier

• ANew Technology Group 10